Unique ID issued by UMIN | UMIN000029478 |
---|---|
Receipt number | R000033679 |
Scientific Title | A phase I/II clinical trial of radical radiotherapy using carbon-ion beams with standard adjuvant therapy for early breast cancer |
Date of disclosure of the study information | 2017/10/10 |
Last modified on | 2019/10/11 22:28:38 |
A phase I/II clinical trial of radical radiotherapy using carbon-ion beams with standard adjuvant therapy for early breast cancer
Breast Cancer II
A phase I/II clinical trial of radical radiotherapy using carbon-ion beams with standard adjuvant therapy for early breast cancer
Breast Cancer II
Japan |
breast cancer
Breast surgery | Radiology |
Malignancy
NO
To evaluate safety and efficacy of the treatment for breast cancer with carbon-ion radiotherapy instead of tumor resection.
Safety,Efficacy
Adverse reaction of normal tissue within 90 days after starting of the treatment.
1. Adverse reaction of normal tissue in late phase
2. Local effect (CR rate)
3. Local control rate with recommended dose
4. Breast cosmetic outcomes
5. Progression-free survival period
6. Overall survival period
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment | Maneuver |
Carbon-ion radiotherapy for breast tumor (no tumor resection). Adjuvant therapy is performed based on the guidelines for breast cancer.
20 | years-old | <= |
Not applicable |
Female
1. Pathologically proven invasive ductal carcinoma or ductal carcinoma in situ.
2. Tumor size <=20 mm on MRI.
3. No massive LVSI or EIC.
4. No lymphenode metastasis (>2 mm). Sentinel lymph node biopsy is performed prior this study.
5. No distant metastasis.
6. Performance status (ECOG) of 0 to 2.
7. 20 years old or older.
8. A life expectancy of at least 6 months.
9. Written informed consent.
1. Severe complication (e.g. uncontroled lung disease, heart disease, infection, or psychiatric disease).
2. Previous treatment history including surgery, chemotherapy, endocrine therapy, molecular-targeted agents for breast cancer in same side.
3. Active other malignancy
4. The distanse between skin surface and tumor (including EIC) <=5 mm.
5. Previous radiation therapy for breast cancer in same side.
6. Eligible patients for "Breast cancer I".
7. Pregnancy, pregnancy potential.
8. Ptinents who are considered inappropriate by the attending physician due to medical, psychological or other factors.
30
1st name | Kumiko |
Middle name | |
Last name | Karasawa |
National Institutes for Quantum and Radiological Sciences and Technology
QSTHospital
285-8555
Anagawa 4-9-1, Inage-ku 263-8555 Chiba, Japan
043-206-3306
kkarasaw@twmu.ac.jp
1st name | Noriyuki |
Middle name | |
Last name | Okonogi |
National Institutes for Quantum and Radiological Sciences and Technology
QST Hospital
263-8555
Anagawa 4-9-1, Inage-ku 263-8555 Chiba, Japan
043-206-3306
okonogi.noriyuki@qst.go.jp
QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology
QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology
Other
National Institutes for Quantum and Radiological Sciences and Technology, Certified Review Board
Anagawa 4-9-1, Inage-ku 263-8555 Chiba, Japan
043-206-3306
okonogi.noriyuki@qst.go.jp
NO
2017 | Year | 10 | Month | 10 | Day |
Unpublished
Open public recruiting
2017 | Year | 10 | Month | 04 | Day |
2017 | Year | 10 | Month | 04 | Day |
2017 | Year | 10 | Month | 10 | Day |
2031 | Year | 03 | Month | 31 | Day |
2017 | Year | 10 | Month | 09 | Day |
2019 | Year | 10 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033679